A to Z Summary Results - Patient Decision Aids - Ottawa Hospital Research Institute 


Patient Decision Aid Summary

Title Whether or not to take levodopa-carbidopa intestinal gel (LCIG) to control the symptoms of Parkinson’s disease (PD). --- Prendre ou non le gel intestinal de levodopa/carbidopa (GILC) pour maîtriser les symptômes de la maladie de Parkinson (MP).
To access it View the patient decision aid on the developer website
Audience Patients with advance Parkinson Disease and their caregivers (if applicable).
Options included TO TAKE levodopa/carbidopa intestinal gel (LCIG).
NOT TO TAKE levodopa/carbidopa intestinal gel (LCIG).
Year of last update or review 2022
Format Web, paper, PDF
Developer Caroline Cayer
Where was it developed? caroline.cayer.ciussse-chus@ssss.gouv.qc.ca
CIUSSS de l'Estrie-CHUS
Canada
Health condition Parkinson's Disease
Language French
Based on 2025 IPDAS criteria (International Patient Decision Aid Standards) this patient decision aid (and/or supporting materials) meets:
7 out of 7 IPDAS Qualifying criteria to be defined as a patient decision aid
5 out of 7 IPDAS Essential criteria to lower the risk of making a biased decision
Not applicable: Other IPDAS Essential criteria for patient decision aids about screening or testing
View IPDAS criteria details.

Last modified: 2025-07-29.